OR WAIT null SECS
February 01, 2024
With the formation of the new R&D unit, Regeneron will assume full development and commercialization rights to 2seventy bio’s preclinical- and clinical-stage cell therapy pipeline.
January 30, 2024
IMU Biosciences has secured £11.5 million in its Series A financing round.
January 29, 2024
The acquisition adds a potential rare disease asset to Sanofi’s alpha-1 antitrypsin deficiency pipeline.
January 24, 2024
Under a new alliance, KBI Biopharma and Argonaut Manufacturing Services will combine their strengths to offer end-to-end biopharma development and CGMP manufacturing solutions.
January 18, 2024
The acquisition will give Novartis full rights to CALY-002, Calypso’s lead product candidate.
January 17, 2024
The acquisition marks a pivotal expansion for the company into the US market.
January 16, 2024
Through the acquisition of Harpoon Therapeutics, Merck will gain an investigational delta-like ligand 3-targeting T-cell engager under development for cancer treatment.
CellVoyant has raised £7.6 million in seed funding to speed up the development of novel cell therapies.
January 15, 2024
Boehringer Ingelheim is investing €120 million (US$131 million) into its Koropi, Greece site to expand production for new therapeutics.
January 11, 2024
Pluri has launched PluriCDMO, a new contract development and manufacturing organization business that will offer cell therapy manufacturing services.